16 April 2019

Ankylosing Spondylitis Biologics

Biosimilar launch will make affordable rituximab a reality

12 April 2019

Analgesics Conditions EULAR Spondyloarthritis

APLAR interviews: RA treatment in 2030

10 April 2019

Conditions Obesity

Collective effort to fight growing obesity

10 April 2019

Public Health

Sorting friend from foe in the war against tobacco

10 April 2019

Pain

APLAR interviews: Education *is* medicine

10 April 2019

DMARDS EULAR

APLAR interviews: Telerheumatology

10 April 2019

Conditions EULAR

APLAR interviews: Takayasu arteritis

10 April 2019

Research

Improving diagnostic accuracy of giant cell arteritis

10 April 2019

EULAR

Too soon for T2T in SpA

10 April 2019

EULAR Spondyloarthritis

The hunt for the perfect predictor

29 March 2019

EULAR

HK society celebrates 30 years of growth

29 March 2019

EULAR

Not just a congress, a collaboration platform

29 March 2019

Evidence Based

How to spot rubbish qualitative research

29 March 2019

Minimally-invasive technique to check OA damage and repair

28 March 2019

Diet Global Health Patient Perspective

Doctors need to get behind the great food transformation

28 March 2019

Analgesics Biologics Conditions Corticosteroids Spondyloarthritis

Take only as directed: high-dose Xeljanz poses PE risk